B. Watson

发表

Synthesis and SAR of novel histamine H3 receptor antagonists.

P. Hipskind, C. Lindsley, D. Sindelar, 2006, Bioorganic & medicinal chemistry letters.

Synthesis and antibacterial activity of the C-7 side chain of 3-aminoquinazolinediones.

H. D. Showalter, M. Huband, M. Shapiro, 2008, Bioorganic & medicinal chemistry letters.

Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints.

D. Timm, L. L. Winneroski, P. May, 2019, Bioorganic & medicinal chemistry.

Preparation and biological evaluation of conformationally constrained BACE1 inhibitors.

D. Timm, L. L. Winneroski, P. May, 2015, Bioorganic & medicinal chemistry.

A First-in-class, Highly Selective and Cell-active Allosteric Inhibitor of Protein Arginine Methyltransferase 6 (PRMT6)

R. Campbell, C. Arrowsmith, M. Schapira, 2020, bioRxiv.

Practical Asymmetric Fluorination Approach to the Scalable Synthesis of New Fluoroaminothiazine BACE Inhibitors

L. L. Winneroski, E. Hembre, P. García-Losada, 2018 .

D-phenylglycinol-derived non-covalent factor Xa inhibitors: effect of non-peptidic S4 linkage elements on affinity and anticoagulant activity.

T. Craft, V. Klimkowski, N. Y. Chirgadze, 2007, Bioorganic & medicinal chemistry letters.

A facile synthesis of substituted 3-amino-1H-quinazoline-2,4-diones

J. Rubin, H. D. Showalter, Rajeshwar Singh, 2005 .

3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms.

J. Domagala, H. D. Showalter, J. Bronstein, 2006, Journal of medicinal chemistry.

Structure-activity relationships of 3-aminoquinazolinediones, a new class of bacterial type-2 topoisomerase (DNA gyrase and topo IV) inhibitors.

J. Domagala, H. D. Showalter, S. Gracheck, 2007, Bioorganic & medicinal chemistry letters.

Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor

James E Audia, R. Dean, T. Lindstrom, 2011, The Journal of Neuroscience.

Discovery of non-covalent dipeptidyl peptidase IV inhibitors which induce a conformational change in the active site.

Brandon J. Margolis, D. Timm, Qing Shi, 2007, Bioorganic & medicinal chemistry letters.

Synthesis and Pharmacological Characterization of 2-(2,6-dichlorophenyl)-1-((1S,3R)-5-(3-hydroxy-3-methylbutyl)-3-(hydroxymethyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one (LY3154207), a potent, subtype selective, and orally available positive allosteric modulator of the human dopamine D1

G. Stephenson, Charles R. Yang, S. Mitchell, 2019, Journal of medicinal chemistry.

Robust Pharmacodynamic Effect of LY3202626, a Central Nervous System Penetrant, Low Dose BACE1 Inhibitor, in Humans and Nonclinical Species

R. Dean, D. McKinzie, L. L. Winneroski, 2022, Journal of Alzheimer's disease reports.

The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans

R. Dean, T. Lindstrom, D. Timm, 2015, The Journal of Neuroscience.

Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.

D. McKinzie, D. Timm, L. L. Winneroski, 2021, Journal of medicinal chemistry.

The synthesis of Z-allylic alcohols via palladium-mediated reactions of stannoxanes with aryl halides

G. Kraus, B. Watson, 1996 .

Assigning structures to diastereomeric aliphatic α,α'-dibromo ketones

T. S. Sorensen, M. Parvez, B. Watson, 2002 .